Incyte (INCY) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Incyte · Health Care · ref. ETF XLV · 51 calls · price $127.74
What the company does: Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
📈 Incyte (INCY) stock price
$127.74+52.6% over range
Aug 28, 25low $81.66 · high $129.93Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
44% recommend buying · 18 analysts
📊 JPI status : Incyte is no longer in our current JPI rankings, but appeared in the past (2018) — its upside may be behind it. See the stocks picked in 2018 →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 INCY price target & analyst consensus — price $128
The price target · all analysts combined (18 targets)
Highest target · 1 firm of 18$155+21.3%
Median target · of 18 targets$118-7.6%
Lowest target · 1 firm of 18$90-29.5%
Current price$127.74
Where these 18 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
844%
$130 ↔ $155
Below
1056%
$90 ↔ $123
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $130 (+1.8 %), call made on July 30, 2026, maturing on July 30, 2027 (29 d ago).
The 12 reliable analysts
$134+4.5 %
The 6 other firms
$104-19 %
How to read it: the 12 reliable firms are not filtered by optimism — 8 aim above the price, 4 below, hence their $134 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 18 ratings (last 6 months)
Strong Buy00%
Buy844%
Hold1056%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 INCY price target all
All 23 calls, one by one, with our verdict on each firm.
→ See all 23 targets, analyst by analyst💡 The best analysts on INCY most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in INCY? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Incyte? The JPI assistant answers using our backtest data.
📈 Incyte fundamentals: valuation, margins & growth › open the full page
P/E 16.3Net margin 27.7 %Revenue growth +37.7 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 10 %
2023
Rev +9%Profit +75%
2024
Rev +15%Profit −95%
2025
Rev +21%Profit +3845%
🔎 Detailed analyses
🏛️ Which US Congress members hold Incyte (INCY)?
1 Congress member has disclosed INCY buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Gilbert Cisneros 1× · 48%
✅ Historical analyst reliability on INCY
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| SunTrust Robinson Humphrey | 100% | +88.5% | 2 |
| Leerink Swann | 100% | +47.2% | 4 |
| JP Morgan ↗ | 100% | +41.3% | 3 |
| Citigroup ↗ | 100% | +29.4% | 6 |
| Guggenheim ↗ | 100% | +24.4% | 3 |
| SVB Leerink | 86% | +14.3% | 7 |
| Nomura | 80% | +26.6% | 5 |
| Goldman Sachs ↗ | 75% | +10.6% | 4 |
| Jefferies ↗ | 71% | +59.1% | 7 |
| Brean Capital | 67% | +31.8% | 3 |
See the other 16 firms
| Piper Sandler ↗ | 0% | -29.9% | 2 |
| Gabelli & Co. | 0% | -25.8% | 2 |
| BMO Capital ↗ | 14% | -21.9% | 7 |
| JMP Securities | 41% | -5.7% | 17 |
| Raymond James ↗ | 50% | -10.0% | 2 |
| TD Cowen ↗ | 50% | -0.5% | 2 |
| RBC Capital ↗ | 50% | +1.1% | 6 |
| Canaccord Genuity ↗ | 50% | +3.3% | 2 |
| Argus Research ↗ | 50% | +7.0% | 2 |
| B of A Securities ↗ | 57% | +34.6% | 7 |
| Morgan Stanley ↗ | 67% | -15.8% | 6 |
| Truist Securities ↗ | 67% | +10.8% | 6 |
| Oppenheimer ↗ | 67% | +16.3% | 12 |
| Credit Suisse | 67% | +19.9% | 3 |
| Barclays ↗ | 67% | +22.9% | 6 |
| UBS ↗ | 67% | +30.2% | 3 |
📊 What $1,000 invested in Incyte would be worth › open the full page
In short — $1,000 invested in Incyte 10 years ago would be worth $1,045 today, i.e. +0%/yr on average. Best year: 2025 (+43%), worst: 2018 (-33%). Price performance, excluding dividends.
If I'd invested $1,000 in Incyte
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,641 | +64% |
| 3 years ago | $1,411 | +41% |
| 5 years ago | $1,303 | +30% |
Return by year (Incyte)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +15% | $1,148 (+15%) |
| 2025 | +43% | $1,641 (+64%) |
| 2024 | +10% | $1,805 (+81%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Incyte
Loading news…
📋 All analyst calls on INCY
Filtered on — · ✕ show all
Canaccord Genuity ↗
Aug 20, 26
▲ Buy · 🎯$152
Price at call : $127.81 — upside +19%
Today : $127.74 — upside +19%
🎯 on INCY : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
HC Wainwright & Co. ↗
Aug 20, 26
▲ Buy · 🎯$150
Price at call : $127.22 — upside +18%
Today : $127.74 — upside +17%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
Piper Sandler ↗
Aug 17, 26
▲ Overweight · 🎯$130
Price at call : $123.47 — upside +5%
Today : $127.74 — upside +2%
🎯 on INCY : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Aug 17, 27
matures : Aug 17, 27
▲ Outperform · 🎯$137
Price at call : $119.8 — upside +14%
Today : $127.74 — upside +7%
🎯 on INCY : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Aug 4, 27
matures : Aug 4, 27
Leerink Partners ↗
Aug 3, 26
▲ Outperform · 🎯$155
Price at call : $118.43 — upside +31%
Today : $127.74 — upside +21%
🎯 on INCY : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
HC Wainwright & Co. ↗
Aug 3, 26
▲ Buy · 🎯$150
Price at call : $118.43 — upside +27%
Today : $127.74 — upside +17%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
RBC Capital ↗
Jul 29, 26
■ Sector Perform neutral · not a buy · 🎯$109
Price at call : $122.99 — gap to target -11%
Today : $127.74 — gap to target -15%
🎯 on INCY : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
Guggenheim ↗
Jul 29, 26
▲ Buy · 🎯$150
Price at call : $122.99 — upside +22%
Today : $127.74 — upside +17%
🎯 on INCY : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
See the other 43 calls, newest to oldest
BMO Capital ↗
Jul 29, 26
■ Market Perform neutral · not a buy · 🎯$130
Price at call : $122.99 — gap to target +6%
Today : $127.74 — gap to target +2%
🎯 on INCY : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
▲ Overweight · 🎯$139
Price at call : $127.1 — upside +9%
Today : $127.74 — upside +9%
🎯 on INCY : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
HC Wainwright & Co. ↗
Jul 29, 26
▲ Buy · 🎯$150
Price at call : $127.1 — upside +18%
Today : $127.74 — upside +17%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
■ Neutral neutral · not a buy · 🎯$110
Price at call : $117.67 — gap to target -7%
Today : $127.74 — gap to target -14%
🎯 on INCY : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Jul 23, 27
matures : Jul 23, 27
Morgan Stanley ↗
Jul 23, 26
■ Equal-Weight neutral · not a buy · 🎯$104
Price at call : $117.67 — gap to target -12%
Today : $127.74 — gap to target -19%
🎯 on INCY : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 23, 27
matures : Jul 23, 27
HC Wainwright & Co. ↗
Jul 21, 26
▲ Buy · 🎯$140
Price at call : $117.39 — upside +19%
Today : $127.74 — upside +10%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Jul 21, 27
matures : Jul 21, 27
▲ Overweight · 🎯$134
Price at call : $114.88 — upside +17%
Today : $127.74 — upside +5%
🎯 on INCY : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 14, 27
matures : Jul 14, 27
BMO Capital ↗
Jul 13, 26
■ Market Perform neutral · not a buy · 🎯$112
Price at call : $114.23 — gap to target -2%
Today : $127.74 — gap to target -12%
🎯 on INCY : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
RBC Capital ↗
Jul 7, 26
■ Sector Perform neutral · not a buy · 🎯$99
Price at call : $117.26 — gap to target -16%
Today : $127.74 — gap to target -22%
🎯 on INCY : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
HC Wainwright & Co. ↗
Jun 29, 26
▲ Buy · 🎯$140
Price at call : $114.66 — upside +22%
Today : $127.74 — upside +10%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Jun 29, 27
matures : Jun 29, 27
■ Neutral neutral · not a buy · 🎯$113
Price at call : $114.66 — gap to target -1%
Today : $127.74 — gap to target -12%
🎯 on INCY : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jun 26, 27
matures : Jun 26, 27
HC Wainwright & Co. ↗
Jun 24, 26
▲ Buy · 🎯$140
Price at call : $108.46 — upside +29%
Today : $127.74 — upside +10%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Jun 24, 27
matures : Jun 24, 27
Truist Securities ↗
Jun 22, 26
■ Hold neutral · not a buy · 🎯$105
Price at call : $104.4 — gap to target +1%
Today : $127.74 — gap to target -18%
🎯 on INCY : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jun 22, 27
matures : Jun 22, 27
BMO Capital ↗
Jun 22, 26
■ Market Perform neutral · not a buy · 🎯$94
Price at call : $103.66 — gap to target -9%
Today : $127.74 — gap to target -26%
🎯 on INCY : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Jun 22, 27
matures : Jun 22, 27
HC Wainwright & Co. ↗
Jun 9, 26
▲ Buy · 🎯$140
Price at call : $105.39 — upside +33%
Today : $127.74 — upside +10%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Jun 9, 27
matures : Jun 9, 27
■ Market Perform neutral · not a buy · 🎯$99
Price at call : $97.1 — gap to target +2%
Today : $127.74 — gap to target -22%
🎯 on INCY : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : May 22, 27
matures : May 22, 27
HC Wainwright & Co. ↗
May 21, 26
▲ Buy · 🎯$135
Price at call : $97.41 — upside +39%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : May 21, 27
matures : May 21, 27
HC Wainwright & Co. ↗
May 4, 26
▲ Buy · 🎯$135
Price at call : $97.14 — upside +39%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : May 4, 27
matures : May 4, 27
Oppenheimer ↗
Apr 29, 26
■ Perform neutral · not a buy · 🎯$90
Price at call : $95.27 — gap to target -6%
Today : $127.74 — gap to target -30%
🎯 on INCY : no call matured yet · 📊 on Health : 44.1% · +0.6% (220 calls)
in progress (365j)
matures : Apr 29, 27
matures : Apr 29, 27
▲ Buy · 🎯$123
Price at call : $99.1 — upside +24%
Today : $127.74 — upside -4%
🎯 on INCY : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Apr 29, 27
matures : Apr 29, 27
HC Wainwright & Co. ↗
Apr 15, 26
▲ Buy · 🎯$135
Price at call : $97.1 — upside +39%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Apr 15, 27
matures : Apr 15, 27
HC Wainwright & Co. ↗
Mar 30, 26
▲ Buy · 🎯$135
Price at call : $90.33 — upside +49%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Mar 30, 27
matures : Mar 30, 27
■ Neutral neutral · not a buy · 🎯$94
Price at call : $92.26 — gap to target +2%
Today : $127.74 — gap to target -26%
🎯 on INCY : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Mar 25, 27
matures : Mar 25, 27
HC Wainwright & Co. ↗
Mar 25, 26
▲ Buy · 🎯$135
Price at call : $92.23 — upside +46%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Mar 25, 27
matures : Mar 25, 27
■ Hold neutral · not a buy · 🎯$94
Price at call : $93 — gap to target +1%
Today : $127.74 — gap to target -26%
🎯 on INCY : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Mar 16, 27
matures : Mar 16, 27
HC Wainwright & Co. ↗
Mar 9, 26
▲ Buy · 🎯$135
Price at call : $97.1 — upside +39%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Mar 9, 27
matures : Mar 9, 27
Evercore ISI Group ↗
Mar 5, 26
■ In-Line neutral · not a buy · 🎯$110
Price at call : $97.33 — gap to target +13%
Today : $127.74 — gap to target -14%
🎯 on INCY : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Mar 5, 27
matures : Mar 5, 27
▲ Overweight · 🎯$117
Price at call : $101.73 — upside +15%
Today : $127.74 — upside -8%
🎯 on INCY : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 18, 27
matures : Feb 18, 27
RBC Capital ↗
Feb 11, 26
■ Sector Perform neutral · not a buy · 🎯$92
Price at call : $100.75 — gap to target -9%
Today : $127.74 — gap to target -28%
🎯 on INCY : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
▲ Buy · 🎯$120
Price at call : $100.75 — upside +19%
Today : $127.74 — upside -6%
🎯 on INCY : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Wells Fargo ↗
Feb 11, 26
■ Equal-Weight neutral · not a buy · 🎯$101
Price at call : $100.75 — gap to target +0%
Today : $127.74 — gap to target -21%
🎯 on INCY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
HC Wainwright & Co. ↗
Feb 11, 26
▲ Buy · 🎯$135
Price at call : $98.84 — upside +37%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Piper Sandler ↗
Feb 6, 26
▲ Overweight · 🎯$110
Price at call : $109.03 — upside +1%
Today : $127.74 — upside -14%
🎯 on INCY : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
HC Wainwright & Co. ↗
Feb 5, 26
▲ Buy · 🎯$135
Price at call : $102.76 — upside +31%
Today : $127.74 — upside +6%
🎯 on INCY : no call matured yet · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Feb 5, 27
matures : Feb 5, 27
▲ Overweight · 🎯$116
Price at call : $102.6 — upside +13%
Today : $127.74 — upside -9%
🎯 on INCY : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Wells Fargo ↗
Jan 20, 26
■ Equal-Weight neutral · not a buy · 🎯$107
Price at call : $102.62 — gap to target +4%
Today : $127.74 — gap to target -16%
🎯 on INCY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jan 20, 27
matures : Jan 20, 27
▲ Buy · 🎯$128
Price at call : $105.95 — upside +21%
Today : $127.74 — upside +0%
🎯 on INCY : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Jan 13, 27
matures : Jan 13, 27
Morgan Stanley ↗
Jan 6, 26
■ Equal-Weight neutral · not a buy · 🎯$94
Price at call : $110.57 — gap to target -15%
Today : $127.74 — gap to target -26%
🎯 on INCY : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jan 6, 27
matures : Jan 6, 27
Morgan Stanley ↗
Dec 8, 25
■ Equal-Weight neutral · not a buy · 🎯$92
Price at call : $95.16 — gap to target -3%
Today : $127.74 — gap to target -28%
🎯 on INCY : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 8, 26
matures : Dec 8, 26
Wells Fargo ↗
Dec 8, 25
▲ Overweight · 🎯$116
Price at call : $95.16 — upside +22%
Today : $127.74 — upside -9%
🎯 on INCY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Dec 8, 26
matures : Dec 8, 26
▲ Outperform · 🎯$121
Price at call : $96.7 — upside +25%
Today : $127.74 — upside -5%
🎯 on INCY : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Dec 8, 26
matures : Dec 8, 26
▲ Overweight · 🎯$115
Price at call : $106.24 — upside +8%
Today : $127.74 — upside -10%
🎯 on INCY : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Nov 24, 26
matures : Nov 24, 26
William Blair ↗
Mar 18, 25
■ Market Perform neutral · not a buy
🎯 on INCY : no call matured yet · 📊 on Health : 63% · +5.2% (27 calls)
in progress (365j)
matures : Mar 18, 26
matures : Mar 18, 26
Frequently asked questions
Should I buy Incyte stock?
This isn't buy advice. For Incyte, the analyst consensus is "Hold", with an average price target of $118 (-8% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Incyte). We show the numbers — you decide.
Is it too late to buy Incyte? How high can it go?
The most bullish analyst target on Incyte is $155 (+21% above today's price); the average is $118. That's the upside they see. Check how reliable those analysts have actually been on Incyte on our site before trusting it.
Is Incyte still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 26 analysts have a real record on Incyte, the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in Incyte? The case for and against
The arguments for and against, one by one, from the numbers: why invest in INCY (and why hesitate).
What has Incyte's past performance been?
Historical returns and a "how much if I had invested" calculator: INCY performance & returns.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX